Winthrop University Hospital
Welcome,         Profile    Billing    Logout  
 106 Trials 
44 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Armstrong, David
COVER DFUs, NCT05372809: Multi-Center, Prospective, Randomized Controlled Trial Evaluating SkinTE® in the Treatment of Wagner 2 DFUs

Terminated
3
42
US
SkinTE, Autologous Heterogeneous Skin Construct, Control, Standard of Care
PolarityTE, Alira Health
Diabetic Foot
02/24
02/24
NCT04267640: Study of AMG0001 to Improve Ulcer Healing and Perfusion in Subjects With Peripheral Ischemic Ulcers

Recruiting
2
60
US
AMG0001, HGF plasmid, Collategene, beperminogene perplasmid, Placebo
AnGes USA, Inc.
Peripheral Artery Disease, Ischaemic Ulcer of Lower Leg Due to Atherosclerotic Disease, Chronic Limb Threatening Ischemia, Ischemic Ulcer of Foot
07/22
01/23
NCT03754465: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Foot Ulcers

Active, not recruiting
2
56
US
ALLO-ASC-DFU, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells, Hydrogel SHEET(Vehicle control), Hydrogel sheet without Allogenic Mesenchymal Stem Cells
Anterogen Co., Ltd.
Diabetic Foot Ulcer
11/23
05/24
NCT04497805: Clinical Study of ALLO-ASC-SHEET in Subjects With Diabetic Wagner Grade II Foot Ulcers

Recruiting
2
64
US
ALLO-ASC-SHEET, Hydrogel sheet containing Allogenic Mesenchymal Stem Cells
Anterogen Co., Ltd.
Diabetic Foot Ulcer
12/24
06/25
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Recruiting
N/A
200
US
NuShield
Organogenesis
Diabetic Foot Ulcer
11/21
12/21
BGWM, NCT06403605: Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

Recruiting
N/A
100
US
Mirragen Wound Matrix, Fibracol
ETS Wound Care, LLC, Professional Education and Research Institute
Diabetic Foot Ulcer, Ulcer Foot, Diabetic Foot
12/24
12/24
GE-MTEC, NCT05796492: Ultrasound Treatment on Wound Healing Time

Terminated
N/A
8
US
Pulsed splenic ultrasound, Active ultrasound, Ultrasound probe (no energy applied)
General Electric Research
Burn Wound, 2nd Degree Burn of the Skin
12/24
12/24
NCT05797285: Evaluating The Efficacy Of A Keratin Graft In Treating Non-Healing Diabetic Foot Ulcers

Completed
N/A
26
US
human keratin graft, ProgenaMatrix
ProgenaCare Global, LLC, Professional Education and Research Institute
Ulcer Healing, Diabetic Foot Ulcer
12/23
12/23
NCT04564443: A Unique Micro Water Jet Technology Device Versus Standard Debridement in the Treatment of Diabetic Foot

Active, not recruiting
N/A
222
US
Medaxis Debritom+, Sharp Surgical Debridement, Additional Outer Dressing Application, Offloading, Pressure Relief, Fibracol Wound Dressing, Calcium Alginate
Medaxis, LLC, Professional Education and Research Institute
Diabetic Foot Ulcer, Diabetic Foot
12/24
12/24
NCT06035523: Clinical Study Evaluating Wound Closure With Endoform™ and Symphony™

Recruiting
N/A
50
US
Endoform™ Antibacterial, Endoform™ Natural, Symphony™
Aroa Biosurgery Limited, Professional Education and Research Institute
Wound Healing, Diabetic Foot, Chronic Foot Ulcer, Foot Ulcer
06/24
06/24
NCT06681428: Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers

Recruiting
N/A
240
US
Allograft
Tides Medical, Professional Education and Research Institute
Diabetic Foot Ulcer (DFU), Chronic Foot Ulcers
11/26
11/26
NCT06035536: Clinical Study Evaluating Symphony™ Versus Standard of Care in the Treatment of Non-Healing Diabetic Foot Ulcers

Recruiting
N/A
120
US
Symphony™ plus Off-loading, Wound Dressing comprising of calcium alginate Fibracol
Aroa Biosurgery Limited, Professional Education and Research Institute
Diabetic Foot, Diabetic Foot Ulcer, Foot Ulcer, Chronic Foot Ulcer
12/24
12/24
HTPN, NCT02299466: Registry for Patients Receiving Intravenous Nutrition at Home

Recruiting
N/A
1000
Canada
University Health Network, Toronto, Canadian Nutrition Society, Baxter Healthcare Corporation, Ontario Medical Supply
Parenteral Nutrition, Home
12/29
12/29
Villella, Jeannine A
PROTA, NCT05271318: Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab and Pegylated Liposomal Doxorubicin as Treatment for Ovarian Cancer.

Recruiting
1
29
Europe, US
TILT-123, Ad5/3-E2F-d24-hTNFa-IRES-hIL2 (TILT-123), pembrolizumab, KEYTRUDA®, MK-3475, pegylated liposomal doxorubicin, PLD
TILT Biotherapeutics Ltd., Merck Sharp & Dohme LLC
Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Sensitive Ovarian Cancer in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Fallopian Tube Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin, Platinum-Sensitive Primary Peritoneal Carcinoma in Which the Participant Has Allergy or Severe Intolerance to Carboplatin and/or Cisplatin
01/25
01/27
Carsons, Steven
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30
Schneider, Jeffrey
TRIUMPH-5, NCT06662383: A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

Recruiting
3
800
Europe, US, RoW
Retatrutide, LY3437943, Tirzepatide, LY3298176
Eli Lilly and Company
Obesity
04/27
04/27
VIVID-2, NCT04232553 / 2019-002687-27: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Recruiting
3
778
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company
Crohn's Disease
11/24
12/26
Be6A Lung-01, NCT06012435: A Study of Sigvotatug Vedotin Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer ().

Recruiting
3
600
Europe, Canada, Japan, US, RoW
sigvotatug vedotin, SGN-B6A; PF-08046047, docetaxel
Seagen Inc.
Carcinoma, Non-Small-Cell Lung
07/26
07/28
Accacha, Siham
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Completed
N/A
250
US
Insulin Pump with Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes
12/23
12/23
Brem, Harold
NCT05797688: Adipose-derived Stem Cells to Treat Chronic Wounds.

Withdrawn
1
US
The Celution System, Celution, Adipose-derived cell processor
Winthrop University Hospital, Cytori Therapeutics
Wound of Skin
07/17
09/17
Katz, Aaron E
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
NCT04025372: INTREPId (INTermediate Risk Erection PreservatIon Trial)

Active, not recruiting
2
234
US
Bicalutamide, GnRH Agonist, Radiation Therapy, Darolutamide
Dana-Farber Cancer Institute, Bayer, Decipher Biosciences
Prostate Cancer
03/25
03/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
Lane, Brian
CLARIFY, NCT06056830: Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

Recruiting
3
383
US, RoW
64Cu-SAR-bisPSMA
Clarity Pharmaceuticals Ltd
Prostate Cancer, Prostatic Neoplasms
02/25
02/25
Schwartz, Richard
BRAVO, NCT04996264: Broad-spectrum Rapid Antidote: Varespladib Oral for Snakebite

Completed
2
96
US, RoW
Varespladib Methyl, LY333013, Placebo, Standard of care (SOC)
Ophirex, Inc., Premier Research Group plc
Snakebites, Envenoming, Envenoming, Snake, Envenomation, Snake
06/23
06/23
PORTICO IDE, NCT02000115: Portico Re-sheathable Transcatheter Aortic Valve System US IDE Trial

Recruiting
N/A
1150
US, RoW
Portico transcatheter aortic valve, Commercially available transcatheter aortic valve
Abbott Medical Devices
Aortic Valve Stenosis
10/19
07/25
CLASP IID, NCT03706833: Edwards PASCAL /IIF Pivotal Clinical Trial

Recruiting
N/A
1247
Europe, Canada, US
Edwards PASCAL System, Transcatheter Mitral Valve repair (TMVr), Abbott Mitraclip System
Edwards Lifesciences
Degenerative Mitral Valve Disease, Mitral Regurgitation, Mitral Insufficiency, Functional Mitral Regurgitation
01/25
04/30
APOLLO, NCT03242642: Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation.

Recruiting
N/A
1056
Europe, Canada, US
Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
Medtronic Cardiovascular
Mitral Valve Regurgitation
10/26
09/36
Ye, Shicong
NCT04244175: A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

Completed
2
154
Europe, US, RoW
CVL-865, Placebo
Cerevel Therapeutics, LLC
Seizures
05/24
05/24
Marston, William
NCT04927702: Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)

Terminated
N/A
47
US
Synthetic Hybrid-Scale Fiber Matrix, Restrata, Standard of Care, Living Cellular Skin Substitute, Apligraf
Acera Surgical, Inc.
Diabetic Foot Ulcer, Venous Leg Ulcer
07/24
08/24
NCT05489588: The GORE® VIAFORT Vascular Stent Iliofemoral Study

Active, not recruiting
N/A
165
US
GORE® VIAFORT Vascular Stent
W.L.Gore & Associates
Venous Thromboses, Venous Disease, Venous Leg Ulcer, Venous Stasis, Venous Ulcer, Venous Stenosis, Venous Occlusion, Vein Thrombosis, Vein Occlusion, Vein Disease
04/25
04/29
Gorenstein, Scott
NCT03855514: Randomized Clinical Study Assessing NuShield Versus Standard of Care in Diabetic Foot Ulcers

Recruiting
N/A
200
US
NuShield
Organogenesis
Diabetic Foot Ulcer
11/21
12/21
NCT05496296: Comparison of Transforming Powder Dressing to NPIAP Recommended Standard of Care Therapies in Stage 2, 3 and 4 Pressure Injuries

Recruiting
N/A
300
US
Altrazeal® Transforming Powder Dressing, Standard of Care wound dressings (such as foam, hydrocolloid, collagen, etc)
ULURU Inc., United States Department of Defense
Pressure Ulcers Stage II, Pressure Ulcers Stage III, Pressure Ulcer, Stage IV
12/23
12/23
Drewes, Wendy
DEFINE AFib, NCT04926857: (Atrial Fibrillation)

Completed
N/A
973
US
Non-Interventional
Medtronic Cardiac Rhythm and Heart Failure
Atrial Fibrillation
01/24
01/24
Desouza, Shilpa
NCT03626688 / 2018-001187-33: A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients

Recruiting
3
1000
Europe, Canada, US, RoW
Ralinepag, APD811, Placebo
United Therapeutics
PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
12/25
12/25
Ilowite, Jonathan
NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Hourglass Feb 2024 - Jun 2024 : Acceptance of regulatory submission in China for CRSwNP
Active, not recruiting
3
1667
Europe, Canada, Japan, US, RoW
GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)
GlaxoSmithKline, Iqvia Pty Ltd
Asthma
10/25
10/25
Koenig, Jan A
NCT06203756: Patient Outcomes With Robotic-Assisted Total Knee Arthroplasty

Active, not recruiting
N/A
642
US
Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex UC, BalanceBot, Apex Knee System, Active Spacer, Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex PS, Omnibotics Robotic-assisted Total Knee Arthroplasty with Apex Revision
Corin
Arthroplasties, Knee Replacement
03/21
04/31
Ghafary, Maryum
QUILT-3.032, NCT03022825: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

May 2023 - May 2023: FDA targt action date for approval in BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Jul 2022 - Jul 2022: Accepted for review for BCG-unresponsive non-muscle-invasive bladder cancer carcinoma in situ based on QUILT-3.032 study
Checkmark Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
Jun 2022 - Jun 2022: Data from QUILT-3.032 trial in combination with BCG for NMIBC at ASCO 2022
More
Active, not recruiting
2/3
190
US
N-803 and BCG, N-803
ImmunityBio, Inc.
Bladder Cancer
04/25
10/28
QUILT-2.005, NCT02138734: A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Recruiting
1/2
596
US
BCG+N-803( 50mg BCG/ Instillation+ N-803( 400 μg/instillation). ), BCG( 50mg/Instillation)
ImmunityBio, Inc.
Non-muscle Invasive Bladder Cancer
12/28
12/38
Pinales, Eymi
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
Ritchie, Angela
NEPTUNUS-1, NCT05350072 / 2020-005661-14: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome

Active, not recruiting
3
276
Europe, US, RoW
VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Sjogren Syndrome
05/25
05/27
Shevchuk, Iryna
SIRIUS-SLE 1, NCT05639114 / 2022-002691-36: Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus

Recruiting
3
406
Europe, Canada, Japan, US, RoW
Ianalumab, VAY736, Placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Systemic Lupus Erythematosus
01/27
04/29
NEPTUNUS-Ext, NCT05985915: A Randomized, Double-blind 2-arm NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Ianalumab (VAY736), VAY736, Placebo
Novartis Pharmaceuticals
Sjogrens Syndrome
08/28
07/30

Download Options